glyceraldehyde 3-phosphate dehydrogenase (304-313) has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hollocks, S; Kouril, T; October, C; Odendaal, C; Snoep, JL; van Niekerk, DD | 1 |
1 other study(ies) available for glyceraldehyde 3-phosphate dehydrogenase (304-313) and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Inhibitor titrations reveal low control of glyceraldehyde 3-phosphate dehydrogenase and high control of hexokinase on glycolytic flux in an aggressive triple-negative breast cancer cell line.
Topics: Cell Line; Glycolysis; Hexokinase; Humans; Lactic Acid; Triple Negative Breast Neoplasms | 2023 |